Pelthos Therapeutics (NYSE:PTHS) reported its fourth-quarter and full-year 2025 financial results, highlighting a period of rapid commercial acceleration for its flagship product, ZELSUVMI™ (berdazimer gel, 10.3%).
Pfizer (NYSE:PFE) today announced positive topline results from its Phase 3 TALAPRO-3 study, evaluating the combination of TALZENNA® (talazoparib) and XTANDI® (enzalutamide).
Theravance Biopharma (NASDAQ:TBPH) on Thursday reported financial results for the fourth quarter and full year ended December 31, 2025, revealing a year of significant financial recovery tempered by a major strategic pivot.
NeurAxis (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for children and adults, announced its financial and operational results for the fourth quarter and full fiscal year ended December 31, 2025.
Aveanna Healthcare Holdings (NASDAQ:AVAH) announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, reporting a period of accelerated growth and significant margin expansion.
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 clinical trial evaluating retatrutide for the treatment of type 2 diabetes.
DarioHealth (NASDAQ:DRIO) today announced its financial results for the fourth quarter and full year ended December 31, 2025, describing the period as a critical "foundation-building" year.
Evotec (NASDAQ:EVO) announced today that it will receive a $10 million milestone payment from Bristol Myers Squibb (NYSE:BMY) following the start of a Phase 1 clinical trial for BMS-986506.
KYO Pharma (NASDAQ:OKYO) reported new exploratory Phase 2a findings for its lead candidate, urcosimod (0.05%), demonstrating that the topical therapy significantly improves the quality of life (QoL) for patients suffering from neuropathic corneal pain (NCP).
Aclaris Therapeutics (NASDAQ:ACRS) announced it has successfully completed patient enrollment for its Phase 2 clinical trial of bosakitug (ATI-045), an investigational treatment for patients suffering from moderate-to-severe atopic dermatitis.
Ovid Therapeutics (NASDAQ:IVID) announced a $60 million private placement to fund the expansion of its clinical pipeline into tuberous sclerosis complex seizures and infantile spasms.
Dogwood Therapeutics (NASDAQ:DWTX) reported its fourth-quarter and full-year 2025 financial results, highlighting a pivot toward late-stage clinical development for its lead analgesic candidate, Halneuron®.
